Loading…
Reported covered position: Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican Secretary
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · third_quarter · 3A
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · second_quarter · 2A
Source: Senate LDA
| CENTER ON BUDGET AND POLICY PRIORITIES | 8 | 2025–2026 |
| CONSUMER TECHNOLOGY ASSOCIATION | 8 | 2025–2026 |
| COUNCIL ON FOUNDATIONS INC. | 8 | 2025–2026 |
| CTIA - THE WIRELESSS ASSOCIATION | 8 | 2025–2026 |
| DAVITA, INC. | 8 | 2025–2026 |
| INTEL CORPORATION | 8 | 2025–2026 |
| KATAHDIN IMPACT INC. | 8 | 2025–2026 |
| LOWE'S COMPANIES INC | 8 | 2025–2026 |
| META PLATFORMS INC (FORMERLY FACEBOOK INC AND VARIOUS SUBSIDIARIES) | 8 | 2025–2026 |
| OSHKOSH CORPORATION | 8 | 2025–2026 |
| PNC FINANCIAL INC. | 8 | 2025–2026 |
| REPUBLIC SERVICES, INC. | 8 | 2025–2026 |
| SHIELD AI | 8 | 2025–2026 |
| VAPOR TECHNOLOGY ASSOCIATION | 8 | 2025–2026 |
| WALGREEN COMPANY | 8 | 2025–2026 |
| WALMART INC | 8 | 2025–2026 |
| GOOGLE CLIENT SERVICES LLC | 7 | 2025–2026 |
| INTEGRAL AD SCIENCE | 7 | 2025 |
| NATIONAL FOOTBALL LEAGUE | 7 | 2025–2026 |
| RTX CORPORATION AND AFFILIATES | 7 | 2025–2026 |
| T-MOBILE USA, INC. | 7 | 2025–2026 |
| CIGAR ASSOCIATION OF AMERICA | 6 | 2025 |
| FAMILIES AGAINST MANDATORY MINIMUMS | 6 | 2025 |
| FANDUEL GROUP | 6 | 2025–2026 |
| HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION | 6 | 2025 |
| LIVE EARTH IMAGING, INC. | 6 | 2025–2026 |
| PRUDENTIAL FINANCIAL INC | 6 | 2025–2026 |
| THE BUSINESS ROUNDTABLE, INC. | 6 | 2025–2026 |
| LKQ CORPORATION | 5 | 2025–2026 |
| WAYMO LLC | 5 | 2025–2026 |
| BROWN-FORMAN CORPORATION | 4 | 2026 |
| BRUNSWICK CORPORATION | 4 | 2025 |
| CONOCOPHILLIPS | 4 | 2026 |
| EXPEDIA GROUP | 4 | 2025 |
| MCKINSEY & COMPANY | 4 | 2025–2026 |
| NOVO NORDISK, INC. | 4 | 2026 |
| SOUTHWEST AIRLINES CO. | 4 | 2026 |
| SWISHER INTERNATIONAL INC. | 4 | 2026 |
| Fresenius Kabi | 3 | 2025 |
| JAPAN TOBACCO INTERNATIONAL USA INC. | 2 | 2026 |
| JPMORGAN CHASE HOLDINGS LLC | 2 | 2026 |
| MARIANA MINERALS | 2 | 2026 |
| THE BOEING COMPANY | 2 | 2026 |
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE BUSINESS ROUNDTABLE, INC. · Firm: S-3 GROUP
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · 1A
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARIANA MINERALS via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to tariffs and importation of counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to compounding and counterfeit drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues regarding permitting reform
Issues regarding permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOUTHWEST AIRLINES CO. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · third_quarter · Q3
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax policy, tariffs, including duty drawbacks
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SWISHER INTERNATIONAL INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues pertaining to tobacco and nicotine; monitoring activity at FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to online sports gaming
Issues relating to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · third_quarter · Q3
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous platforms for border and national security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to privacy
Issues related to trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KATAHDIN IMPACT INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the park service and efficient use of federal lands
Advocating for advanced super intelligence academic computing, regional consortiums, and CREATES Act
Issues related to the advancement of Artificial Intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · third_quarter · Q3
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · third_quarter · Q3
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR RESPONSIBLE LENDING via S-3 GROUP
2026 · third_quarter · Q3
Issues related to financial products and lending
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER ON BUDGET AND POLICY PRIORITIES via S-3 GROUP
2026 · third_quarter · Q3
Issues related to tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · third_quarter · Q3
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to trade and tariffs
Issues related to support for domestic chipmakers in NDAA
Issues related to Inter Partes Review and patent litigation at the ITC
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF COMMUNITY HEALTH PLANS via S-3 GROUP
2026 · third_quarter · Q3
Issues related to healthcare; Medicare Advantage and Medicaid
Issues related to healthcare; Medicare Advantage and Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BUSINESS ROUNDTABLE, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to trade and tariff policy; issues relating to Russia sanctions
Tax, trade, economic issues, and government funding
Issues relating to artificial intelligence
MCKINSEY & COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Raising awareness related to company activities and business
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RTX CORPORATION AND AFFILIATES via S-3 GROUP
2026 · third_quarter · Q3
FY26 Defense Appropriations and Authorizations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
META PLATFORMS, INC. (FORMERLY FACEBOOK, INC. AND VARIOUS SUBSIDIARIES) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL FOOTBALL LEAGUE via S-3 GROUP
2026 · third_quarter · Q3
Legislative and regulatory issues affecting the professional sports industry, such as player health and safety, antitrust, intellectual property, and sports betting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE HOLDINGS LLC via S-3 GROUP
2026 · third_quarter · Q3
Issues related to banking and financial services and Financial Services Appropriations
Issues related to the budget and the implementation of financial services legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES, LLC via S-3 GROUP
2026 · third_quarter · Q3
Issues related to human trafficking efforts and criminal justice reform
Issues related to intellectual property enforcement
Issues related to competition in online services
T-MOBILE USA, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BOEING COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues addressed in FY27 Appropriations / NDAA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to tariffs and importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs.
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues regarding permitting reform
Issues regarding permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOUTHWEST AIRLINES CO. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
JAPAN TOBACCO INTERNATIONAL USA INC. via S-3 GROUP
2026 · second_quarter · Q2
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
Monitor trade, tax issues and regulations
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SWISHER INTERNATIONAL INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues pertaining to tobacco and nicotine; monitoring activity at FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues relating to tax
Issues related to online sports gaming
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous platforms for border and national security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KATAHDIN IMPACT INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the advancement of Artificial Intelligence
Issues related to the park service and efficient use of federal lands
Development and expansion of National AI a multi-state consortium focused on advanced compute
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · second_quarter · Q2
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · second_quarter · Q2
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR RESPONSIBLE LENDING via S-3 GROUP
2026 · second_quarter · Q2
Issues related to financial products and lending
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER ON BUDGET AND POLICY PRIORITIES via S-3 GROUP
2026 · second_quarter · Q2
Issues related to tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · second_quarter · Q2
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to support for domestic chipmakers in NDAA
Issues related to semiconductor competitiveness
Issues related to trade and tariffs
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues related to consumer data privacy, and children's privacy
General educational meetings on policy issues impacting tech platforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE OF COMMUNITY HEALTH PLANS via S-3 GROUP
2026 · second_quarter · Q2
Issues related to healthcare; Medicare Advantage and Medicaid
Issues related to healthcare; Medicare Advantage and Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BUSINESS ROUNDTABLE, INC. via S-3 GROUP
2026 · second_quarter · Q2
Privacy issues
Issues related to corporate and international tax; H.R.1 One Big Beautiful Bill Act of 2025
Tax, trade, economic issues, and government funding
MCKINSEY & COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Raising awareness related to company activities and business
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RTX CORPORATION AND AFFILIATES via S-3 GROUP
2026 · second_quarter · Q2
FY26 Defense Appropriations and Authorizations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
META PLATFORMS, INC. (FORMERLY FACEBOOK, INC. AND VARIOUS SUBSIDIARIES) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL FOOTBALL LEAGUE via S-3 GROUP
2026 · second_quarter · Q2
Legislative and regulatory issues affecting the professional sports industry, such as player health and safety, antitrust, intellectual property, and sports betting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JPMORGAN CHASE HOLDINGS LLC via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the budget and the implementation of financial services legislation
Issues related to banking and financial services and Financial Services Appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES, LLC via S-3 GROUP
2026 · second_quarter · Q2
Issues related to human trafficking efforts and criminal justice reform
Issues related to intellectual property enforcement
Issues related to funding in Appropriations bills and internet governance
T-MOBILE USA, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BOEING COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues addressed in FY27 Appropriations / NDAA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARIANA MINERALS via S-3 GROUP
2026 · third_quarter · RR
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
LIVE EARTH IMAGING INC. via S-3 GROUP
2026 · first_quarter · 1T
Issues related to satellites
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to tariffs and importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues regarding permitting reform
Issues regarding permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOUTHWEST AIRLINES CO. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SWISHER INTERNATIONAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues pertaining to tobacco and nicotine; monitoring activity at FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues relating to tax
Issues related to online sports gaming
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · first_quarter · Q1
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous platforms for border and national security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KATAHDIN IMPACT INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to the park service and efficient use of federal lands
Development and expansion of National AI a multi-state consortium focused on advanced compute
Issues related to the advancement of Artificial Intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to R&D tax credit
Issues related to funding for CHIPS Act
Issues related to semiconductor competitiveness
Issues in support for STEM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to corporate and international tax
Issues relating to capital allocation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to funding in Appropriations bills and internet governance
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitor trade, tax issues and regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding for CHIPS Act
Issues related to R&D tax credit
Issues in support for STEM
Issues related to Inter Partes Review and patent litigation at the ITC
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to artificial intelligence
Issues related to trade and tariff policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to competition in online services
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues relating to the domestic production of critical minerals and supply-chain resiliency
Issues related to commercial aviation, FAA, and Transportation Security Administration
Issues related to commercial aviation, FAA, and Transportation Security Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE